| Literature DB >> 19093279 |
Maria A Petrisko1, Jonathan D Skoner, David P Skoner.
Abstract
Inhaled corticosteroids (ICS) are the guideline-preferred preventative therapy for persistent asthma of all severity levels and for all ages, including children. While these drugs are unquestionably efficacious, concerns of adverse systemic effects limit patient compliance with treatment regimens and thus the attainable benefits. Suppression of bone growth, bone density, and HPA axis function, in addition to cataract formation and elevated intraocular pressure/glaucoma, have been associated with ICS use. This review will focus on recent developments in the safety and efficacy of ICS as compared to oral CS corticosteroids and the achievement of a balance between risk and benefit in optimizing ICS therapy.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19093279 DOI: 10.1080/02770900802631361
Source DB: PubMed Journal: J Asthma ISSN: 0277-0903 Impact factor: 2.515